Abstract：
Total meniscectomy for treating massive meniscal tears may lead to joint instability, cartilage degeneration, and even progressive osteoarthritis. The meniscal substitution strategies for advancing reconstruction of the meniscus deserve further investigation.
A decellularized meniscal scaffold (DMS) modified with collagen affinity stromal cell-derived factor (C-SDF1α) may facilitate meniscal regeneration and protect cartilage from abrasion.
Controlled laboratory study.
The authors first modified DMS with C-SDF1α to fabricate a new meniscal graft (DMS-CBD [collagen-binding domain]). Second, they performed in vitro studies to evaluate the release dynamics, biocompatibility, and differentiation inducibility (osteogenic, chondrogenic, and tenogenic differentiation) on human bone marrow mesenchymal stem cells. Using in vivo studies, they subjected rabbits that received medial meniscectomy to a transplantation procedure to implement their meniscal graft. At postoperative weeks 6 and 12, the meniscal regeneration outcomes and chondroprotective efficacy of the new meniscal graft were evaluated by macroscopic observation, histology, micromechanics, and immunohistochemistry tests.
In in vitro studies, the optimized DMS-CBD graft showed notable biocompatibility, releasing efficiency, and chondrogenic inducibility. In in vivo studies, the implanted DMS-CBD graft after total meniscectomy promoted the migration of cells and extracellular matrix deposition in transplantation and further facilitated meniscal regeneration and protected articular cartilage from degeneration.
The new meniscal graft (DMS-CBD) accelerated extracellular matrix deposition and meniscal regeneration and protected articular cartilage from degeneration.
The results demonstrate that the DMS-CBD graft can serve as a potential meniscal substitution after meniscectomy.
A decellularized meniscal scaffold (DMS) modified with collagen affinity stromal cell-derived factor (C-SDF1α) may facilitate meniscal regeneration and protect cartilage from abrasion.
Controlled laboratory study.
The authors first modified DMS with C-SDF1α to fabricate a new meniscal graft (DMS-CBD [collagen-binding domain]). Second, they performed in vitro studies to evaluate the release dynamics, biocompatibility, and differentiation inducibility (osteogenic, chondrogenic, and tenogenic differentiation) on human bone marrow mesenchymal stem cells. Using in vivo studies, they subjected rabbits that received medial meniscectomy to a transplantation procedure to implement their meniscal graft. At postoperative weeks 6 and 12, the meniscal regeneration outcomes and chondroprotective efficacy of the new meniscal graft were evaluated by macroscopic observation, histology, micromechanics, and immunohistochemistry tests.
In in vitro studies, the optimized DMS-CBD graft showed notable biocompatibility, releasing efficiency, and chondrogenic inducibility. In in vivo studies, the implanted DMS-CBD graft after total meniscectomy promoted the migration of cells and extracellular matrix deposition in transplantation and further facilitated meniscal regeneration and protected articular cartilage from degeneration.
The new meniscal graft (DMS-CBD) accelerated extracellular matrix deposition and meniscal regeneration and protected articular cartilage from degeneration.
The results demonstrate that the DMS-CBD graft can serve as a potential meniscal substitution after meniscectomy.
摘要：
■用于治疗大量半月板撕裂的全半月板切除术可能导致关节不稳定，软骨退化，甚至进行性骨关节炎。用于推进半月板重建的半月板替代策略值得进一步研究。
■用胶原亲和基质细胞衍生因子（C-SDF1α）修饰的脱细胞半月板支架（DMS）可以促进半月板再生并保护软骨免受磨损。
■对照实验室研究。
■作者首先用C-SDF1α修饰DMS，以制造新的半月板移植物（DMS-CBD[胶原蛋白结合域]）。第二,他们进行了体外研究以评估释放动力学，生物相容性，和分化诱导性(成骨，软骨形成,和张力分化）对人骨髓间充质干细胞。利用体内研究，他们对接受内侧半月板切除术的兔子进行移植手术，以实施半月板移植。在术后6周和12周，通过宏观观察评估新半月板移植物的半月板再生结果和软骨保护功效，组织学,微观力学,和免疫组织化学测试。
■在体外研究中，优化的DMS-CBD移植物显示出显著的生物相容性，释放效率，和软骨形成诱导性。在体内研究中，全半月板切除术后植入的DMS-CBD移植物促进了细胞的迁移和细胞外基质的沉积,并进一步促进了半月板的再生和关节软骨的退变.
■新型半月板移植物（DMS-CBD）加速了细胞外基质沉积和半月板再生，并保护了关节软骨免于变性。
■结果表明，DMS-CBD移植物可以在半月板切除术后作为潜在的半月板替代。
■用胶原亲和基质细胞衍生因子（C-SDF1α）修饰的脱细胞半月板支架（DMS）可以促进半月板再生并保护软骨免受磨损。
■对照实验室研究。
■作者首先用C-SDF1α修饰DMS，以制造新的半月板移植物（DMS-CBD[胶原蛋白结合域]）。第二,他们进行了体外研究以评估释放动力学，生物相容性，和分化诱导性(成骨，软骨形成,和张力分化）对人骨髓间充质干细胞。利用体内研究，他们对接受内侧半月板切除术的兔子进行移植手术，以实施半月板移植。在术后6周和12周，通过宏观观察评估新半月板移植物的半月板再生结果和软骨保护功效，组织学,微观力学,和免疫组织化学测试。
■在体外研究中，优化的DMS-CBD移植物显示出显著的生物相容性，释放效率，和软骨形成诱导性。在体内研究中，全半月板切除术后植入的DMS-CBD移植物促进了细胞的迁移和细胞外基质的沉积,并进一步促进了半月板的再生和关节软骨的退变.
■新型半月板移植物（DMS-CBD）加速了细胞外基质沉积和半月板再生，并保护了关节软骨免于变性。
■结果表明，DMS-CBD移植物可以在半月板切除术后作为潜在的半月板替代。
